PMID: 9542527Jul 1, 1997Paper

Death of solid tumor cells induced by Fas ligand expressing primary myoblasts

Somatic Cell and Molecular Genetics
A Hofmann, H M Blau

Abstract

Anticancer therapy for solid tumors suffers from inadequate methods for the localized administration of cytotoxic agents. Fas ligand (FasL) has been reported to be cytotoxic to a variety of cells, including certain tumor cell lines. We therefore postulated that myoblasts could serve as non-transformed gene therapy vehicles for the continuous localized delivery of cytotoxic anticancer agents such as FasL. However, contrary to previous reports, fluorescence activated cell sorting (FACS) analyses revealed that both primary mouse and human myoblasts express Fas, the receptor for FasL. To avoid self-destruction and test the cytotoxic potential of myoblasts, the cells were isolated from mice deficient in Fas (lpr/lpr), the mouse counterpart of human autoimmune lymphoproliferative syndrome (ALPS). These primary mouse myoblasts were transduced with a retroviral vector encoding mouse FasL and expression of a biologically active and soluble form of the molecule was confirmed by the apoptotic demise of cocultured Fas-expressing Jurkat cells, the standard in the field. To test whether the lpr myoblasts expressing FasL could be used in anticancer therapy, human rhabdomyosarcoma derived cell lines were assayed for Fas and then tested in the ...Continue Reading

References

Jan 1, 1987·Cytogenetics and Cell Genetics·E C DouglassA A Green
Nov 17, 1995·Science·T S GriffithT A Ferguson
Apr 1, 1994·European Journal of Immunology·F RamsdellD H Lynch
Mar 10, 1995·Science·S Nagata, P Golstein
Aug 1, 1995·European Journal of Immunology·A Rensing-EhlA Fontana
Oct 19, 1995·Nature·D BellgrauR C Duke
Feb 1, 1997·Nature Medicine·K SeinoH Yagita
Feb 7, 1997·Cell·S Nagata
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·J AllisonD L Vaux
Feb 1, 1997·Transplantation Proceedings·K SeinoH Yagita
Dec 31, 1997·Science·S M KangH M Blau

❮ Previous
Next ❯

Citations

Dec 6, 2014·Journal of Hematology & Oncology·Giovanni Luca GravinaClaudio Festuccia
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·K AokiG J Nabel
Mar 7, 2007·Journal of Cellular Biochemistry·Rishi Raj Chhipa, Manoj Kumar Bhat
Feb 19, 2000·Microscopy Research and Technique·D Skuk, J P Tremblay
Jan 10, 2003·Cell Transplantation·Daniel SkukJacques P Tremblay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Lymphoproliferative Syndrome

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fas mediated apoptosis. Discover the latest research on ALPS here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis